Moderna Strengthens Commercial Strategy As Pipeline Advances

Moderna announced organizational changes with President Stephen Hoge taking expanded oversight of R&D, manufacturing, and commercial operations. The company reported Q1 adjusted loss of $1.18 per share (better than expected) and revenue of $389 million (exceeding estimates). Moderna reiterated 2026 revenue growth guidance of up to 10% and expects potential launches of three new products in 2027-2028, including flu-COVID combination and norovirus vaccines. The company also anticipates key clinical milestones for its oncology and rare disease candidates.